Menu
Despite decades of intensive research, biologics cannot be dosed orally limiting their enormous therapeutic potential. This is because of insufficient oral bioavailability.
We can systematically identify the best possible drug candidate and delivery system to maximize oral bioavailability through our GI-ORIS™ robotic screening technology.
Gastrointestinal Organ Robotic Interface System (GI-ORIS™) enables us to maintain porcine GI tissue integrity and use it for high throughput screening studies. We have a large library of oral drug delivery systems and are able to systematically identify the best drug candidate and drug delivery system for maximal oral bioavailability.
790 Memorial Drive Suite 300, Cambridge, MA 02139 | Wagistrasse 13, 8952 Schlieren, Switzerland
Oral drug delivery of biologics remains a largely unresolved challenge due to low oral bioavailability caused by the inability of biologics to pass through the Gl mucus layer and tissue as well as being rapidly degraded by enzymes in the GI tract. Despite decades of research, our ability to create drug delivery systems to allow biologics to penetrate the mucus layer and be absorbed by the underlining tissue are hindered by the enormous complexity of these structures which are to date still not fully understood.
Our proprietary platform, called the gastrointestinal robotic interface system (GI-ORIS) enables us to capture the entire complexity of the GI tract in a microwell plate that can be used for fully automated screening experiments. This enables us to test thousand of samples in a single day, which would take multiple years without our technology. Evaluating different drug candidates and >10.000 drug delivery systems that we have available combined with data analysis and AI, we can systematically identify the best possible drug delivery system and drug candidates to achieve high oral bioavailability.